TCRT Stock Explodes As Alaunos Lands $350M Velaris Deal

Alaunos Therapeutics Inc. stocks have been trading up by 9.63 percent amid heightened optimism over its cancer therapy pipeline.

Live Update At 12:32:25 EDT: On Friday, October 16, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 9.63%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TCRT just went from quiet micro-cap to full-on momentum story, but traders still need to respect the fundamentals. Alaunos Therapeutics reported tiny quarterly revenue of about $5,000 against roughly $952,000 in operating expenses. That’s classic early-stage biotech: almost no sales, heavy research and admin costs, and deep losses. Basic EPS sits near -$0.41, and key returns like return on equity and return on assets are sharply negative, showing the business is still far from profitability.

On the balance sheet, TCRT listed about $124,000 in cash at the 2026/06/30 period end, with working capital around -$198,000. That cash level looked thin before the Velaris Therapeutics deal and the $350M private placement. Financial strength ratios back that up: a current ratio of 0.8 and quick ratio of 0.1 tell traders this was a cash-starved company needing fresh funding.

Now the capital raise changes that runway story. With the new $350M expected to fund Alaunos Therapeutics operations into 2029, TCRT shifts from worrying about survival to focusing on execution of its expanded cardiopulmonary pipeline. For traders, that pivot is driving today’s chart.

Why Traders Are Watching TCRT After The Velaris Deal

TCRT has suddenly become one of the wildest tickers on the screen. Alaunos Therapeutics closed its acquisition of Velaris Therapeutics, picking up a pipeline of ActRII‑Fc ligand traps and biologics aimed at pulmonary arterial hypertension and related cardiopulmonary diseases. At the same time, Alaunos locked in about $350M through a private placement of Series C non‑voting convertible preferred stock, with management signaling that cash should cover operations into 2029 and push several candidates, including VLR199, through early proof‑of‑concept and initial filings.

The market reaction tells you exactly how traders feel about that combo. Reports peg TCRT up between 126% and roughly 225% on extremely heavy trading volume once the news hit. That kind of squeeze‑style move usually means two things: shorts scrambling to cover and momentum traders piling in.

You can see the shockwave in the daily chart. As recently as late September, TCRT was chopping around $0.90–$1.20. On 2026/10/12 it closed at $1.05, then exploded to a $3.03 close on 2026/10/13 as the Velaris Therapeutics story spread. The next two days were what we often see in biotech runners: massive range, from a $4.40 high down to sub‑$2 intraday, finishing 2026/10/16 near $2.39.

Intraday, the 5‑minute candles show TCRT sliding from the premarket $3.00 zone toward the mid‑$2s, then grinding around $2.30–$2.70 with repeated spikes that quickly faded. That’s classic “day two and three” action for a news‑driven biotech — big range, heavy liquidity, and plenty of opportunity for disciplined day traders who respect risk.

Conclusion

For TCRT, this is a reset moment. Alaunos Therapeutics now controls a broader cardiopulmonary pipeline from Velaris Therapeutics and has roughly $350M earmarked to fuel operations into 2029 and advance VLR199 and other candidates through key early milestones. That gives TCRT what many small biotechs lack: time and capital to execute a clear plan.

At the same time, the core numbers remind traders what they’re dealing with. Alaunos Therapeutics still generates minimal revenue, posts steep operating losses, and leans on external funding rather than cash flow. The extended runway lowers near‑term financing risk, but clinical, regulatory, and execution risks remain very real. When TCRT moves 100%–200% in a day on news, both upside and downside swings can be violent.

For active traders, the message is simple: treat TCRT like a high‑volatility biotech play, not a steady compounder. Trade the chart, track the news, and size positions so you can survive the inevitable air pockets. As millionaire penny stock trader and teacher Tim Sykes says, “Consistency is key in trading; don’t let emotions dictate your trades.” As Tim Sykes loves to say, “The hype comes and goes, but disciplined traders who cut losses quickly and stick to their patterns are the ones who last.” This coverage of Alaunos Therapeutics and TCRT is for educational and research purposes only, not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks